Denosumab for the prevention of osteoporotic fractures in postmenopausal women
| Status: |
In progress |
| Expected date of issue: |
TBC |
| Referral date: |
November 2008 |
| Wave: |
20 |
| Process: |
STA |
Topic area:
-
Injuries, accidents and wounds
-
Musculoskeletal
|
NICE project team
| Executive Lead: |
Andrew Dillon
|
| Technical Lead: |
Faye McCracken
|
| Communications manager: |
Alice Law
|
| Project manager: |
Kate Moore
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
TBC |
| 1st appraisal committee meeting: |
27 April 2010 |
Consultees and Commentators
|
Consultees
|
Commentators (no right to submit or appeal)
|
|
Manufacturers/sponsors
Patient/carer groups
- National Osteoporosis Society
Professional groups
- British Health Professionals in Rheumatology
- British Society for Rheumatology
- Primary Care Rheumatology Society
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Society for Endocrinology
Others
- Department of Health
- Coventry Teaching PCT
- Welsh Assembly Government
|
General
- NHS Quality Improvement Scotland
Comparator manufacturer(s)
- Novartis (calcitonin, zoledronic acid)
- Pfizer (lasofoxifene)
- Roche (calcitriol, ibandronic acid)
Relevant research groups
Evidence Review Group
- Aberdeen HTA Group
- National Institute for Health Research Health Technology Assessment Programme
Associated Guideline Groups
Associated Public Health Groups
|
|
Key documents
|
|
|
This page was last updated: 01 March 2010 |
